DUBLIN--(BUSINESS WIRE)--The "Global Analgesics Market Size, Share & Industry Trends Analysis Report By Type, By Route of Administration, By Regional Outlook and Forecast, 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.
The Global Analgesics Market size is expected to reach $42.6 billion by 2028, rising at a market growth of 6.6% CAGR during the forecast period.
Analgesics, or painkillers, are drugs that are used to cure and relieve pain in the body. They are utilized when the suffering is extreme and the patient can no longer take it. Opioids, non-opioids, and compound analgesics (a mix of opioids and non-opioids) are the most often used topical analgesics worldwide. The most powerful painkillers are opioid medicines, which are developed from opium. They're only available with a prescription and are usually utilized to treat moderate to severe pain. Non-opioid drugs, on the other hand, are made out of acetaminophen rather than opium. NSAIDs (non-steroidal anti-inflammatory medicines) are another class of treatments often used to relieve mild to moderate pain.
Increased rates of chronic diseases, such as tuberculosis, cardiovascular disorders, cancer, and arthritis are driving the expansion of the analgesics market. In addition, infectious disorders, such as respiratory, gastrointestinal, and neurological disorders are causing a significant increase in the number of patients.
As the prevalence of these disorders rises, so does the demand for painkillers, which is predicted to drive the analgesics market share even higher. Additionally, an increase in investment from commercial and government organizations for the production of drug manufacturing segments, as well as an increase in R&D activities for the innovation of analgesic goods, has boosted the growth of the analgesics market.
According to the World Health Organization, AIDS and malaria cost the lives of nearly 1.5 million people worldwide in 2020. Tuberculosis affects ten million people each year. Despite the fact that tuberculosis is a preventable and treatable infection, 1.5 million people die from it each year, making it the leading infectious killer on the planet. Analgesics, which primarily contain opioid medications, are also in high demand due to cardiovascular illnesses and cancer.
Market Growth Factors
Rising incidences of chronic pain across the world
Physical pain is a prevalent problem all around the world. According to NCBI5, 20% of people all over the world suffer from some form of physical pain, with 10% of those identified with chronic pain for the first time each year. However, the issue of pain has been mostly considered as a medical problem, with public health paying little attention to it. The prevalence, frequency, and broad-ranging social and health consequences of pain mandate that the public health system pays particular attention to it. As a result, healthcare providers, as well as public health practitioners, is expected to have an increased understanding of pain along with the most effective public health as well as social policy solutions.
Rising demand for strong agonists
A pharmaceutical substance that activates certain brain receptors is known as an agonist. These agonists induce a robust physiological/pharmacological response even when just a limited number of receptors are activated, indicating that the medicine has high intrinsic activity. Strong agonist analgesics, including opioids, like encompass fentanyl, morphine, dihydromorphinone, oxycodone, and oxymorphone. The global health system was wrought havoc by COVID-19. During the pandemic, health organizations all over the world were aimed at regulating infection and addressing COVID-19 patients, which resulted in the suspension of elective surgeries and consultations, putting a strain on hospital and pain clinic pain services.
Market Restraining Factors
Risk of overdose and addiction
Due to the prevalence of deaths caused by drug overdose involving opioids and other analgesics remains high, researchers and governments around various countries continue to monitor opioid overdose deaths. Opioids caused about 50,000 deaths in 2019, more than six times the number of opioid-related fatal overdoses in 1999.
It's crucial to determine and identify which substances are implicated in an overdose, how often they're present, and how their presence changes over time. By recognizing drug involvement, practitioners can better identify effective prevention and response activities. Overdose death data has traditionally been analyzed using the National Vital Statistics System mortality data (NVSS-M), with the combined classifications of semi-synthetic, natural, and synthetic opioids
Scope of the Study
Market Segments Covered in the Report:
By Type
- Non-opioids
- Opioids
By Route of Administration
- Oral
- Transdermal
- Intravenous
- Topical
- Rectal
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
- AbbVie, Inc.
- Reckitt Benckiser Group PLC
- Abbott Laboratories
- Johnson & Johnson
- Bayer AG
- Endo International PLC
- GlaxoSmithKline PLC
- Pfizer, Inc.
- Sanofi S.A.
- Eli Lilly And Company
For more information about this report visit https://www.researchandmarkets.com/r/1aal9g
